Regression Mapping of Association between the Human Leukocyte Antigen Region and Graves Disease  by Simmonds, Matthew J. et al.
Am. J. Hum. Genet. 76:157–163, 2005
157
Report
Regression Mapping of Association between the Human Leukocyte
Antigen Region and Graves Disease
Matthew J. Simmonds,1,* Joanna M. M. Howson,3,* Joanne M. Heward,1 Heather J. Cordell,3
Helen Foxall,1 Jackie Carr-Smith,1 Sarah M. Gibson,1 Neil Walker,3 Yaron Tomer,4
Jayne A. Franklyn,1 John A. Todd,3 and Stephen C. L. Gough1,2
1Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham, and 2Birmingham Heartlands Hospital,
Birmingham, United Kingdom; 3Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge
Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; and 4Division of Endocrinology, Diabetes and Bone
Diseases, Department of Medicine, Mount Sinai School of Medicine, New York
The human leukocyte antigen class II genes DRB1, DQB1, and DQA1 are associated with Graves disease (GD),
but, because of strong linkage disequilibrium within this region, the primary etiological variant(s) remains unknown.
In the present study, 871 patients with GD and 621 control subjects were genotyped at the DRB1, DQB1, and DQA1
loci. All three loci were associated with GD ( , , and , re-512 55 512P p 1.45 # 10 P p 3.20 # 10 P p 9.26 # 10
spectively). Stepwise logistic-regression analysis showed that the association could be explained by either DRB1 or
DQA1 but not by DQB1. To extend previous results, the amino acid sequence of the exon 2–encoded peptide-
binding domain of DRB1 was predicted for each subject, and, by use of logistic regression, each position was
analyzed for association with GD. Of 102 amino acids, 70 were uninformative; of the remaining 32 amino acids,
13 were associated with GD (P values ranged from to ). The strongest association was54 5122.20 # 10 1.2 # 10
at position b74. This analysis is consistent with the possibility that position b74 of exon 2 of the DRB1 molecule
may have a specific and central role in autoantigen presentation by DRB1 to T lymphocytes. However, we cannot
yet exclude a primary role for DQA1 or for other polymorphisms that affect DRB1 function or expression.
Graves disease (GD [MIM 275000]) is a common auto-
immune disease that affects 0.5%–1% of Western popu-
lations (Tunbridge et al. 1977; Gough 2000) and results
from a failure to maintain immune tolerance to thyroid
antigens. Genomewide linkage scans have suggested the
segregation of multiple susceptibility loci (Tomer et al.
1999; Sakai et al. 2001), but only two loci—the human
leukocyte antigen (HLA) region on chromosome 6p21
and the cytotoxic T lymphocyte–associated 4 gene
(CTLA4 [MIM 123890]) on chromosome 2q33—have
been confirmed (in case-control association studies) as
playing primary roles in the susceptibility to GD. For
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CTLA4, disease susceptibility has been mapped to a
noncoding 6.1-kb 3′ region of the gene (Ueda et al.
2003).
The HLA class II gene region encodes a number of
heterodimeric receptors expressed on B lymphocytes,
macrophages, dendritic cells, thymic epithelial cells, and
activated T lymphocytes. Class II molecules are attrac-
tive primary candidates for etiological determinants of
GD because of their involvement in both antigen presen-
tation in the periphery and in thymic selection—namely,
deletion of potentially autoreactive T cells and positive
selection of a T-cell repertoire, some of which may be
capable of recognizing self-epitopes and causing auto-
immune damage in genetically susceptible individuals
(Weetman and McGregor 1994). Reports of association
of the HLA class II region with GD—in particular, the
alleles DRB1*03 (Bech et al. 1977) and DQA1*0501
(Yanagawa et al. 1993) and the DRB1*03-DQB1*02-
DQA1*0501 haplotype—have been consistent in both
case-control and family studies (Heward et al. 1998) and
have produced relative risks (RRs) of 1.9–3.8 (Gough
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Table 1
ORs and 95% CIs for the Alleles
of HLA-DRB1, HLA-DQB1,
and HLA-DQA1
Gene and Allele(s) OR (95% CI)
HLA-DRB1a:
0301–5 2.98 (2.26–3.92)
1001 2.44 (.58–10.17)
0801–11 2.16 (1.25–3.74)
1601–6 2.09 (.84–5.20)
1101–21 2.03 (1.43–2.87)
0101–4 1.80 (1.32–2.45)
0401–22 1.58 (1.20–2.09)
1501–5 1.52 (1.14–2.04)
1301–22 1.45 (1.05–2.00)
1201–3 1.17 (.58–2.36)
1401–21 1.04 (.62–1.76)
0901 1.01 (.52–1.94)
0701 1.00b
HLA-DQB1c:
02 2.56 (1.67–3.91)
04 2.88 (1.47–5.64)
0301/4 2.29 (1.49–3.52)
05 2.17 (1.39–3.38)
0601–9 1.80 (1.18–2.75)
0302 1.68 (1.05–2.68)
03032 1.00b
HLA-DQA1d:
0501–02 2.53 (1.95–3.27)
0601 2.77 (.48–15.93)
0401 2.48 (1.37–4.47)
0101/4 1.64 (1.22–2.21)
0102–3 1.51 (1.16–1.97)
03011–12 1.49 (1.13–1.96)
0201 1.00b
NOTE.—Alleles DQB1*0305 and
DQA1*0302 were detected only in one
individual and so were not used in the
statistical analysis.
a The overall P value for association
with GD was .121.45 # 10
b The least susceptible allele is used
as reference.
c The overall P value for association
with GD was .53.20 # 10
d The overall P value for association
with GD was .129.26 # 10
2000). DRB1*08 has also been associated with GD in
a small North American white population, but this find-
ing awaits confirmation (Chen et al. 1999). In addition,
the DRB1*07 allele has been negatively associated (RR
!1) with GD, which is suggestive of a protective effect
against development of the disease (Chen et al. 1999).
The primary etiological variants in the HLA region,
however, remain unknown, largely because of the strong
linkage disequilibrium (LD) between the class II alleles
and other variants in the region and the fact that sys-
tematic mapping of the region is still in the early stages.
Unrelated white patients of British origin with GD
were recruited from thyroid clinics within Great Britain,
as described elsewhere (Heward et al. 1998). Patients were
defined as having GD by the presence of biochemical
hyperthyroidism together with either the presence of dys-
thyroid eye disease or a diffuse goitre and a significant
titre of microsomal, thyroglobulin, or thyroid-stimulat-
ing-receptor autoantibodies. Ethnically matched control
subjects with no personal history of autoimmune disease
were bled at geographically matched sites. All control
subjects had normal thyroid function and were negative
for thyroid autoantibodies. All patients and subjects gave
informed written consent; the local ethics committee ap-
proved the project.
DNA was prepared from whole blood by use of
the Nucleon BACC II kit from Tepnel Life Sciences.
The HLA-DRB1 (MIM 142857), HLA-DQB1 (MIM
604305) and HLA-DQA1 (MIM 146880) alleles were
amplified using the phototyping method of PCR, as pub-
lished elsewhere (Bunce et al. 1995). Primers were ob-
tained from Sigma-Genosys, and results were visualized
on a 1% ethidium-bromide–stained agarose gel under
UV light.
Unless otherwise stated, statistical analysis was per-
formed within STATA, with routines written by David
Clayton of the University of Cambridge. Odds ratios
(ORs) with 95% CIs for both alleles and genotypes at
the three loci were calculated using logistic regression
(as suggested by Cordell and Clayton [2002]).
A total of 871 patients with GD and 621 control sub-
jects were successfully genotyped at all the DRB1, DQB1,
and DQA1 loci. All three loci were associated with GD,
regardless of whether the alleles ( for12P p 1.45 # 10
DRB1, for DQB1, and5P p 3.20 # 10 P p 9.26 #
for DQA1) (table 1) or the genotypes (1210 P p
for DRB1, for DQB1, and52.21 # 10 P p .01 P p
for DQA1) (table A1 [online only]) were82.72 # 10
modeled. The DRB1*03 (OR 2.98; 95% CI 2.26–3.92)
and DQA1*0501–02 (OR 2.53; 95% CI 1.95–3.27) al-
leles were the most positively associated (with use of
DRB1*07 and DQA1*0201 alleles, respectively, as a
reference). There was some evidence of increased risk
associated with the DRB1*08 alleles, ranked second
(with an OR significantly 11) to the DRB1*03 alleles
(OR 2.16; 95% CI 1.25–3.74) (table 1), with use of
DRB1*07 as a reference. An increase in the frequency
of the DRB1*03-DQB1*02-DQA1*0501 haplotype was
observed in patients with GD, compared with control
subjects (OR 1.45; 95% CI 1.20–1.75), whereas a de-
crease in the frequency of the DRB1*07-DQB1*02-
DQA1*0201 haplotype was observed in patients with
GD, compared with control subjects (OR 0.51; 95% CI
0.40–0.66).
A stepwise logistic-regression approach was used to
test whether the associations at the DRB1, DQB1, and
DQA1 loci could be explained by a single locus (Cordell
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Table 2
Genotype and Allele ORs and 95% CIs for Protective and Susceptible Alleles
at HLA-DRB1
DRB1
GENOTYPE
CASE:
CONTROL
SUBJECT
FREQUENCY
OR (95% CI) USING REFERENCE
03/03 07/07 X/X
03 475:206 2.98 (2.26–3.92) 1.00a 1.85 (1.52–2.26)
X 1,122:849 1.61 (1.28–2.03) .54 (.44–.66) 1.00a
07 145:187 1.00a .34 (.26–.44) .62 (.49–.78)
03/03 45:11 1.00a 9.09 (3.26–25.37) 3.49 (1.77–6.87)
03/X 351:154 .56 (.28–1.11) 5.06 (2.26–11.38) 1.94 (1.52–2.48)
X/X 339:289 .29 (.15–.56) 2.61 (1.17–5.81) 1.00a
07/03 34:30 .28 (.12–.63) 2.52 (1.00–6.37) .97 (.58–1.62)
07/X 93:117 .19 (.10–.40) 1.77 (.77–4.06) .68 (.49–.93)
07/07 9:20 .11 (.04–.31) 1.00a .38 (.17–.86)
NOTE.—Category X includes all alleles not listed. DRB1*03 codes for DRB1*0301–
28; DRB1*07 codes for DRB1*0701–8.
a These alleles were used as reference.
and Clayton 2002). Two analyses of the data were un-
dertaken: one in which the loci were modeled using al-
leles and the other in which they were modeled using
genotypes. The model used did not affect the outcome
of the study. The most associated locus—the one with
the smallest P value—was put in the logistic model. The
other two loci were added one at a time, and a likeli-
hood-ratio test was used to test whether either of them
improved the model. A P value !.01 was considered sug-
gestive of an improvement in the model. When an allele-
based model containing DRB1 was used, addition of
neither DQB1 ( ) nor DQA1 ( ) signifi-P p .15 P p .90
cantly improved the model. Similarly, when DQA1 was
used in the model as the best locus, neither DQB1 nor
DRB1 improved the model ( and , re-P p .04 P p .05
spectively). Conversely, DQB1 was improved by both
DRB1 ( ) and DQA1 (8P p 1.88 # 10 P p 3.99 #
). These results indicate that DQB1 is not a primary810
locus in the class II region. Similar results were obtained
when the loci were modeled by genotype. With DRB1
as the best locus, neither DQA1 nor DQB1 improved
the model ( and , respectively). Like-P p .28 P p .13
wise, when DQA1 was entered into the regression model
as the best locus, addition of DRB1 or DQB1 did not
improve the model ( and , respective-P p .35 P p .36
ly). Again, DQB1 was improved by both DQA1 (P p
) and DRB1 ( ).6 54.06 # 10 P p 2.71 # 10
After we found that either DRB1 or DQA1 could
explain the associations reported in table 1, we tested
whether phase was important. Two-locus haplotypes were
reconstructed using Sinnwell and Schaid’s haplo.stats
package for R, and a likelihood-ratio test was used to
test for haplotype-dependent or cis interactions between
phased and unphased genotypes. DRB1-DQA1 haplo-
types with frequency !0.5% were grouped, as were ge-
notypes with frequency !0.5% at DRB1. No evidence
of haplotype-specific effects was found ( ).P p .10
Allele and genotype ORs at the DRB1 loci are shown
in table 2. DRB1*X or DRB1*X/DRB1*X (where X p
any DRB1 locus except DRB1*03 or DRB1*07) was
used as reference. One copy of the DRB1*03 allele in-
creased the risk of GD (OR 1.94; 95% CI 1.52–2.48),
and two copies further increased this risk (OR 3.49; 95%
CI 1.77–6.87). Conversely, one copy of DRB1*07 de-
creased disease risk (OR 0.68; 95% CI 0.49–0.93), and
two copies further decreased this risk (OR 0.38; 95%
CI 0.17–0.86). The protective effect of the DR7 hap-
lotype was seen even in the absence of the DRB1*03
allele (OR 0.66; 95% CI 0.51–0.85). These data suggest
that the susceptible and protective alleles are working
in a multiplicative manner to increase or decrease disease
risk, respectively. The results also showed that the pres-
ence of one copy of each allele (DRB1*03/DRB1*07
heterozygote) neither increased nor decreased disease
risk (OR 0.97; 95% CI 0.58–1.62), when compared with
the reference genotype.
Allele and genotype ORs at the DQA1 loci are
shown in table 3. Testing DQA1 by use of DQA1*X
or DQA1*X/DQA1*X (where X p any DQA1 locus
except DQA1*05 or DQA1*02) as reference, with an
OR of 1, we saw a similar effect. A single copy of
DQA1*05 increases the risk of GD (OR 2.10; 95% CI
1.63–2.70), whereas two copies further increase the risk
(OR 2.31; 95% CI 1.55–3.42). In contrast to DRB1*07,
two copies of DQA1*02 are needed to significantly de-
crease the risk of GD (OR 0.34; 95% CI 0.14–0.82).
The results also showed that the presence of one copy
of each allele (DQA1*05/DQA1*02 heterozygote) nei-
ther increased nor decreased disease risk (OR 1.00; 95%
CI 0.64–1.55), when compared with the reference ge-
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Table 3
Genotype and Allele ORs and 95% CIs for Protective and Susceptible Alleles
at HLA-DQA1
DQA1
GENOTYPE
CASE:
CONTROL
SUBJECT
FREQUENCY
OR (95% CI) USING REFERENCE
05/05 02/02 X/X
05 645:316 1.00a 2.52 (1.95–3.27) 1.63 (1.37–1.93)
X 954:746 .61 (.52–.73) 1.55 (1.22–1.96) 1.00a
02 143:180 .40 (.31–.51) 1.00a .65 (.51–.82)
05/05 104:44 1.00a 6.75 (2.66–17.12) 2.31 (1.55–3.42)
05/X 389:181 .91 (.61–1.35) 6.14 (2.55–14.78) 2.10 (1.63–2.70)
X/X 242:236 .43 (.29–.64) 2.93 (1.22–7.06) 1.00a
05/02 48:47 .43 (.25–.74) 2.92 (1.13–7.55) 1.00 (.64–1.55)
02/X 81:93 .37 (.23–.58) 2.49 (1.00–6.19) .85 (.60–1.20)
02/02 7:20 .15 (.06–.38) 1.00a .34 (.14–.82)
NOTE.—Category X includes all alleles not listed. DQA1*05 codes for DQA1*0501–
5; DQA1*02 codes for DQA1*0201.
a These alleles were used as reference.
notype. The presence of the DRB1*07 haplotype, there-
fore, appears to cancel out DRB1*03 susceptibility. Sev-
eral mechanisms are possible, such as (1) epitope stealing
by DRB1*07 haplotype DR or DQ molecules, (2) dom-
inant negative selection in the thymus of a DRB1*03
autoantigenic epitope, (3) DRB1*07 haplotype–driven
selection of protective T-regulatory cells in the thymus,
or (4) some other unique feature of the DRB1*07 hap-
lotype, DRB1, or DQA1 alleles, such as regulation of
their expression.
To extend previous results that specifically implicate
DRB1 position b74 in GD susceptibility (Ban et al. 2004),
we used the regression methods in our larger data set to
predict the specific amino acid identity of the exon 2–
encoded domain of DRB1 for each subject. We used
amino acid sequences of the mature protein of the dif-
ferent DRB1 molecules from the IMGT/HLA Sequence
Database. Since exon 2 varied in size between the dif-
ferent DRB1 subtypes, all subtypes were aligned to
DRB1*0301, such that position 1 of each DRB1 type
was relative to the position of the first amino acid in
exon 2 that formed the DRB1 peptide–binding environ-
ment of DRB1*0301. When all the DRB1 exons were
aligned, a 102-aa sequence map was produced. Because
of the resolution limitations of the phototyping method
used to analyze the DRB1 locus (Bunce et al. 1995), a
generic sequence of the DRB1 molecule was constructed
for the given loci with amino acid sequence variation in
a group of specific subtypes, and the amino acid at that
given position was coded as “missing.” For example,
our subtyping method could not distinguish between the
different DRB1*04 subtypes; therefore, at amino acid
position b74, where there is the potential to have glu-
tamate (Glu), alanine (Ala), leucine (Leu), or arginine
(Arg) (for DRB1*0406, DRB1*0408, DRB1*0412, and
DRB1*0422, respectively), the amino acid was scored
as a zero at this position in all DRB1*04-positive sub-
jects. Likewise, at position b74, we were unable to dis-
tinguish Leu from Ala, the amino acids corresponding
to DRB1*08 alleles. We also established a genotyping
assay to determine Arg positivity at position b74. Since
Arg is present only in individuals with DRB1*03 (except
DRB1*0311, DRB1*0317, and DRB1*0324) and with
subtypes DRB1*0422 and DRB1*1107, these results
enabled us to infer results for a larger proportion of our
data set, dependent on DRB1 status obtained from pre-
vious typing. Amplicons that contained the DRB1-bind-
ing domain b74 were amplified with forward primer 5′-
TAC CGG GCG GTG ACG GAG TG-3′ and reverse
primer 5′-CAC CAA CCC CGT AGT TGT GTC TGC-
3′ (Sigma-Genosys) within an MJ Research thermal cy-
cler, by use of a program that consisted of an initial
denaturation step of 94C for 5 min, followed by 30
cycles of 94C for 30 s, 60C for 30 s, and 72C for 30
s. A final step of 72C for 5 min was performed. The
reactions were performed in a volume of 25 ml that con-
tained 200 ng of DNA, 25 pmol of each primer, 0.3 U
Taq polymerase, 2 mM MgCl2, and 200 mM dNTPs.
The amplicon was 121 bp in length and was visualized
on a 2% agarose gel and then was subjected to RFLP
with MspI, in accordance with manufacturer conditions
(New England Biolabs). The products were then visu-
alized on a 3% agarose gel, and unambiguous genotypes
were assigned accordingly.
Logistic-regression analysis was used to perform a sin-
gle-locus association analysis at each of the amino acid
positions encoded by DRB1 exon 2. Amino acids were
modeled as alleles, which assumed a multiplicative mode
of inheritance, and also as genotypes, in which no par-
ticular mode of inheritance was assumed. Since the mul-
tiplicative model relied on fewer degrees of freedom (the
number of alleles minus 1) compared with the genotype
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model, which requires more degrees of freedom (the num-
ber of genotypes minus 1), the multiplicative model is
more powerful and therefore was preferred. However, a
likelihood-ratio test was performed to verify that there
was no significant difference at the 5% level between
the two models. When there was a significant difference,
the full model was employed. Of the 102 amino acid
positions analyzed, 66 were nonpolymorphic. A further
four amino acids positions—b51, b57, b60, and b77—
had three or fewer polymorphisms in the control popula-
tions and had no polymorphisms in the cases. For the
purpose of this analysis, therefore, these four amino ac-
ids were also classed as nonpolymorphic, so our data
set comprised a total of 70 nonpolymorphic or uninfor-
mative amino acids. Logistic-regression disease-associa-
tion analysis was performed for the remaining 32 amino
acid positions. Because of the large number of tests being
performed, a P value of .001 was used as a cutoff for
evidence of association. With that criterion, the regres-
sion analysis identified 13 amino acid positions associ-
ated with disease (b10, b11, b12, b13, b14, b25, b26,
b30, b32, b47, b58, b71, and b74), with P values rang-
ing from for b58 to for b74.4 122.20 # 10 1.22 # 10
A two-locus stepwise logistic-regression analysis (Cor-
dell and Clayton 2002) was performed for a number of
the polymorphic amino acid positions, in an attempt to
evaluate the effects of LD between the various alleles
that encode these nonsynonymous SNPs. Because of the
missing data at certain positions, we confined our analy-
sis to loci with complete information in at least 300 in-
formative cases and 300 control subjects, which resulted
in 98% power, with an allele frequency of 10%, an OR
of 2, and a P value of .05. Eleven amino acid positions
(b12, b14, b25, b27, b31, b32, b33, b62, b74, b76, and
b82), including five of the disease-associated amino ac-
ids, fulfilled this criterion and were appropriate for the
two-locus analysis. Since b74 was the most associated
amino acid ( ), we selected that posi-12P p 1.2 # 10
tion as the best locus; we employed stepwise logistic
regression to test whether any amino acid positions im-
proved the model when b74 was included. Each amino
acid position was added in turn; none of the 10 re-
maining amino acids improved the model (P p .05–
.64). Stepwise logistic-regression analysis was employed
again, to test whether b74 improved a model that in-
cluded each of the other 10 amino acid positions. Each
model was tested in turn, and position b74 improved
every other locus ( to ), which13P p .004 P p 5.4 # 10
indicates that LD with b74 can account for the disease
associations of the other 10 amino acid positions of
DRB1.
Our data, therefore, are consistent with the possibility
that DRB1 position b74 is a primary determinant of sus-
ceptibility to GD. However, even though we have used
both a larger sample size than those of previous studies
and efficient regression approaches, we cannot rule out
the possibility that the HLA association is due to varia-
tion at the DQA1 locus, to a combination of DQA1
and DRB1 variation, or to some other variation at the
DRB1 locus, including other SNPs within exon 2 or
variation outside exon 2. Moreover, at position b74,
no other DRB1 molecules except DRB1*03 (and sub-
types DRB1*0422 and DRB1*1107) contain a posi-
tively charged Arg at b74, and only DRB1*07 allotypes
(and DRB1*0311, DRB1*0317, and DRB1*0324 sub-
types of DRB1*03) contain a noncharged polar Gln at
that position. Unfortunately, alleles that could help fur-
ther test the candidacy of b74, such as DRB1*0422 and
DRB1*1107, were too rare in our sample (0.7% of cases
and 0.4% of controls) to allow meaningful statistical
analysis. The inability to fully resolve phase-known al-
lele status remains a significant limitation in these fine-
mapping studies. DRB1*07 also contains amino acids
at positions b11, b13, and b30 (glycine [Gly], phenyl-
alanine [Phe], and Leu, respectively) that are different
from the rest of the DRB1 types, but these do not vary
significantly in either size or charge, in comparison with
the other nonassociated DRB1 subtypes. The positive
association of DRB1*08 alleles (Leu or Ala at position
b74) suggests that the simple model of Arg versus Gln
at position b74 cannot fully explain the association of
the HLA class II region with GD. Nevertheless, our find-
ing that the phase of DRB1-DQA1 haplotypes is not a
significant factor in the HLA association with GD in the
sample studied does reduce the likeliness of the existence
of an additional disease locus that was untyped in our
study and is in LD with DRB1 or DQA1.
Notwithstanding the caveats discussed above, findings
of prior genetic and functional studies make b74 a strong
candidate. It has been suggested that b74 directly influ-
ences TCR binding, which provides a site-specific mimic
of a side-chain recognition site sufficient for TCR acti-
vation (Nepom et al. 1996). Studies of CLIP (which is
a cleaved peptide from the invariant chain that partici-
pates in class II peptide-binding functions) accumulation
in binding grooves of DRB1 molecules have shown that
when the Arg that is present at b74 is mutated to Gln,
the binding ability of the molecule to CLIP is increased
(Doebele et al. 2003). Amino acid position b74 also spans
several binding environments involved in autoantigen
binding/presentation and T-cell antigen-receptor dock-
ing and interaction (Chelvanayagam 1997). Regarding
type 1 diabetes (T1D [MIM 222100]), it has been es-
tablished that DRB1*0403 and DRB1*0406 alleles pro-
vide a lower risk of disease, compared with the high-
risk DRB1*0401 allele (Awata et al. 1992; Cucca et
al. 1993, 1995, 2001), with variation at position b74 in
the P4-binding pocket seen between the lower-risk
DRB1*0403 and DRB1*0406 alleles, which contain a
negatively charged Glu, compared with the high-risk
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DRB1*0401 allele, which contains a noncharged polar
Ala. Position b74 also encompasses part of the shared
epitope region in the P4-binding pocket that is associated
with rheumatoid arthritis (RA [MIM 180300]) (Greger-
sen et al. 1987). The DRB1*07 haplotype is also nega-
tively associated with T1D and RA (Cavan et al. 1993;
Weyand et al. 1995; Zhao et al. 1996). Complete se-
quence determination in very large sample sizes and ad-
ditional functional studies will be required to further
distinguish between the various explanations for the as-
sociation of the HLA region with GD and other HLA-
associated disorders.
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